Close Menu

NEW YORK – OpGen announced Thursday that its subsidiary Curetis has received CE marking for its SARS-CoV-2 Kit with PULB.

The company is launching the kit in Europe. 

The RT-PCR kit qualitatively detects the virus from oropharyngeal and nasopharyngeal swabs and works with isolated RNA or swabs treated with PCR-Compatible Universal Lysis Buffer, or PULB, which is provided in the kit. Offering PULB allows labs to bypass the need for extraction equipment and reagents, OpGen said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.